



NEWS RELEASE

## Shattuck Labs Announces Two Poster Presentations at UEG Week 2026

2026-10-13

AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced two upcoming poster presentations at United European Gastroenterology (UEG) Week 2026, taking place October 17–20, 2026, in Barcelona, Spain.

### Presentation Details

**Format:** Moderated poster presentation

**Title:** Development and Characterization of SL-846: A Half-Life Extended, Dual-Receptor (DR3 x IL23RA) Targeting Bispecific Antibody

**Presenter:** Mahmud Hussain, Ph.D., Director, R&D of Shattuck Labs

**Date/Time:** October 19, 2026; 1:00–2:00 p.m. CEST

**Format:** ePoster presentation

**Title:** Soluble TL1A/Anti-TL1A Immune Complexes Induce De Novo Production of TL1A and Induce Anti-Drug Antibodies That Cross-Bind Approved IBD Antibodies

**Presenter:** Suresh de Silva, Ph.D., Chief Scientific Officer of Shattuck Labs

**Date/Time:** October 17–20, 2026 (available for viewing throughout the congress)

The posters will be available under Events & Presentations in the Investor Relations section of the Company's website at [www.shattucklabs.com](http://www.shattucklabs.com) following the congress.

### About Shattuck Labs, Inc.

Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck's expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham,

North Carolina. For more information, please visit: [www.ShattuckLabs.com](http://www.ShattuckLabs.com).

**Investor & Media Contact:**

Andrew R. Neill  
Chief Financial Officer  
Shattuck Labs, Inc.  
[InvestorRelations@shattucklabs.com](mailto:InvestorRelations@shattucklabs.com)

Source: Shattuck Labs, Inc.